Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi Cohort Phase IB/II Clinical Study of Pazopanib Combined With Palbociclib for Third Line and Beyond Treatment of Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1)

NCT06895733 is registered in ClinicalTrials.gov with Tianjin Medical University Second Hospital as lead sponsor.

NCT NCT06895733
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06895733 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi Cohort Phase IB/II Clinical Study of Pazopanib Combined With Palbociclib for Third Line and Beyond Treatment of Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1)
Lead sponsor
Tianjin Medical University Second Hospital
Phase
Phase 1/2
Overall status
Recruiting
Start date
November 27, 2024
Completion date
December 31, 2025
Enrollment
65 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

next-generation sequencing, precision medicine, solid tumor, adult